Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on June 28, 2018, regarding events occurring on June 27, 2018. The filing addresses the outcome of a shareholder vote at the reconvened 2018 Annual Meeting of Shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholders voted on Proposal 3 to amend the Company's Charter to increase authorized common stock from 50,000,000 to 100,000,000 shares. The proposal failed to receive sufficient votes for passage. The voting breakdown was as follows:
- For: 14,162,742
- Against: 10,009,774
- Abstain: 255,998
- Total Outstanding Shares Entitled to Vote: 31,744,439
There were no broker non-votes for this proposal.
Outlook, Management Commentary, and Future Actions
Following the failed vote, the Company intends to call a Special Meeting of Shareholders to approve a new amendment to its Charter to increase the number of authorized shares. Management indicated that the increase sought in the Special Meeting is expected to be smaller than the previously requested 50,000,000 share increase. The Company plans to file preliminary and final proxy statements with the SEC regarding this Special Meeting.
Investor Verification Checklist
- Verify the specific number of authorized shares proposed in the upcoming Special Meeting proxy materials.
- Review the Definitive Proxy Statement filed on April 23, 2018, for the original rationale behind the capital increase.
- Monitor the timing of the Special Meeting and the release of the Special Meeting Proxy Materials.
- Confirm the current number of outstanding shares (31,744,439 as of the record date) to assess dilution impact of any future authorization.